MedTrace Logo

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

NCT03648814 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-08-21

No results posted yet for this study

Summary

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Conditions

  • Glaucoma, Neovascular
  • Vascular Endothelial Growth Factor Overexpression

Interventions

PROCEDURE

Intracameral injection

A/C injection of 1.25 mg/0.05 mL bevacizumab

PROCEDURE

Intravitreal injection

Vitreous injection of 1.25 mg/0.05 mL bevacizumab

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Principal Investigators

  • Assoc.Prof.Weerawat Kiddee, MD · Prince of Songkla University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2026-07-01
Completion
2026-07-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03648814 on ClinicalTrials.gov